Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 1 art units • 1 examiners • 0 of 4 (0%) have an AI response strategy ready
Exogenique Co. Ltd. has 4 pending office actions concentrated in the Biotechnology & Pharmaceuticals technology area. All of these actions are assigned to 1 distinct examiner and 1 distinct art unit. This indicates a centralized examination process for this company, where multiple patent applications are being reviewed by the same technical authority. This concentration in 1 art unit can lead to a uniform application of prior art and legal standards across the company's active matters.
PEEBLES, KATHERINE is the busiest examiner for this portfolio, handling 4 pending office actions. This examiner is responsible for the company's pending matters. For the practitioner, this means that the outcome of the pending portfolio currently rests with this individual, making the examiner's specific prosecution history and preferences critical to the company's overall strategy. Managing 4 pending office actions with a single examiner allows for a consistent dialogue but also increases the impact of that examiner's individual perspective.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 3 (75%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PEEBLES, KATHERINE | 4 | 35.5% | +48.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18133886 | NOVEL USE OF MILK EXOSOMES | PEEBLES, KATHERINE | 3d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18133886 | NOVEL USE OF MILK EXOSOMES | PEEBLES, KATHERINE | 3d overdue |
| 17780391 | NOVEL USE OF MILK EXOSOMES | PEEBLES, KATHERINE | 2d overdue |
| 18133901 | NOVEL USE OF MILK EXOSOMES | PEEBLES, KATHERINE | 19d |
| 18133918 | NOVEL USE OF MILK EXOSOMES | PEEBLES, KATHERINE | — |
| Art Unit | Apps |
|---|---|
| 1614 | 4 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18133918 | NOVEL USE OF MILK EXOSOMES | PEEBLES, KATHERINE | 1614 | §103DP | Non-Final OA | — | Pending | Apr 12, 2023 |
| 18133886 | NOVEL USE OF MILK EXOSOMES | PEEBLES, KATHERINE | 1614 | §103§112Other | Non-Final OA | 3d overdue | Pending | Apr 12, 2023 |
| 18133901 | NOVEL USE OF MILK EXOSOMES | PEEBLES, KATHERINE | 1614 | §103DP | Non-Final OA | 19d | Pending | Apr 12, 2023 |
| 17780391 | NOVEL USE OF MILK EXOSOMES | PEEBLES, KATHERINE | 1614 | §103DP | Non-Final OA | 2d overdue | Pending | May 26, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial